泮托拉唑鈉水合物
| 中文名稱 | 泮托拉唑鈉水合物 |
|---|---|
| 中文同義詞 | 泮托拉唑鈉倍半結(jié)晶水合物;特賣 【廠家供應(yīng)】純天然 泮托拉唑鈉水合物;泮托拉唑鈉水合物|泮托拉唑鈉水合物醫(yī)藥級(jí)99%;泮托拉唑鈉水合物164579-32-2含量99%;泮托拉唑鈉水合物164579-32-2|醫(yī)藥級(jí)99%;優(yōu)質(zhì)|泮托拉唑鈉水合物|醫(yī)藥級(jí)99%;泮托拉唑鈉水合物1;泮托拉唑鈉水合物 |
| 英文名稱 | PantoprazoleSodiumSesquihydrate |
| 英文同義詞 | 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-, sodium salt, hydrate (2:3);Unii-6871619Q5x;6-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt hydrate (2:2:3);SKF-96022 SODIUM HYDRATE;Pantoprazole sodium sesquihydrate CRS;Pantoprazole for system suitability CRS;BY1023 (sodium hydrate);Pantoprazole Sodium sesqui hydrate- IP/BP/USP |
| CAS號(hào) | 164579-32-2 |
| 分子式 | C16H18F2N3NaO5S |
| 分子量 | 425.38 |
| EINECS號(hào) | 1312995-182-4 |
| 相關(guān)類別 | 植物提取物;其他科研原料藥;醫(yī)藥中間體;醫(yī)藥原料;醫(yī)藥原料 用于消化性潰瘍出血;原料藥;原料;日用化學(xué)品;化學(xué)試劑 |
| Mol文件 | 164579-32-2.mol |
| 結(jié)構(gòu)式 |  |
泮托拉唑鈉水合物 性質(zhì)
| 儲(chǔ)存條件 | 4°C, protect from light |
|---|---|
| 溶解度 | 易溶于水和乙醇（96%），幾乎不溶于己烷。 |
| 形態(tài) | 固體 |
| 顏色 | 白色至米白色 |
| 主要應(yīng)用 | 藥物（小分子） |
| InChI | 1S/C16H16F2N3O4S.Na.H2O/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;;/h3-7,15-16,21H,8H2,1-2H3;;1H2/q-1;+1; |
| InChIKey | QHNXIKDJFYGZTL-UHFFFAOYSA-N |
| SMILES | [Na+].FC(F)Oc1cc2c(cc1)[N-]C(N2)[S](=O)Cc3nccc(c3OC)OC.O |
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells.
Pantoprazole sodium hydrate can block exosome release. Pantoprazole sodium hydrate inhibits the activity of V-H
+
-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin.
Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats.
| Animal Model: | Mice bearing MCF-7 or A431 xenografts |
| Dosage: | 200 mg/kg |
| Administration: | IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.) |
| Result: |
Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
Significantly increased tumor growth delay with a single dose with Doxorubicin. There is no effect on growth delay alone. |
安全信息
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-17507BR | 泮托拉唑鈉水合物 Pantoprazole sodium hydrate (Standard) | 164579-32-2 | 50 mg | 333元 |
| 2026/06/05 | HY-17507BR | 泮托拉唑鈉水合物 Pantoprazole sodium hydrate (Standard) | 164579-32-2 | 100 mg | 500元 |